



CAPA eNewsletter



CHINESE AMERICAN PATHOLOGISTS ASSOCIATION

~ 全美华人病理学会 ~

VOLUME 3 ISSUE 3 2017

In this issue:

A Note from President	P1
A Letter to CAP Today	P2
The Response from Ms. Driscoll and Letter from Dr. Friedberg.	P3
The CAPA Chicago Course 2017	P4-8
Brief Report of CAPA Dali meeting	P8
Open Letter for Potential CAPA Sponsors	P9
Recent Achievements from CAPA Members	P10-11
Notice for Future Meeting	P11
Case of Quarter (COQ)	P12-13
Recipes of Quarter (ROQ)	P14
Acknowledgements and Advertisements for CAPA Sponsors	P15-16

Editing Team:

Huan-You Wang
Fan Chen
Yanxia Li
Guilan Chen
Hui Guan

Designer and Editor-in-Chief:

Fan Chen




A Note from President

The third CAPA diagnostic Pathology Course "Hot and Practical Topics in Diagnostic Pathology" was successfully held from August 19-20, 2017 in Chicago. One hundred and twenty six members have registered for and participated in this meeting. Dr. Liang Cheng gave the opening keynote speak on the Update of Molecular Pathology for General Pathologists at this meeting. Over 40 speakers presented in this meeting. Besides didactic presentation in all major subspecialties, there were also additional sections for case presentation, forensics and artificial intelligent and so on. There are also sections on career development hosted by Dr. Lirong Cheng and Dr. Andy Ke and photograph hosted by Dr. Ximing Yang and Dr. Xiaoping Sun. This is truly another memorable event for CAPA.

I want to express my sincere thanks to those who make this event possible. First, to our CAPA education committee, especially to Dr. Wei Xin for the excellent program; and to Dr. He Wang and Dr. Lanjing Zhang for obtaining the CME for this course. Second, to Dr. Ximing Yang for arranging a free auditorium for this meeting and getting us the discounted downtown hotel for our participants. Third, to Dr. Guoping Cai and his team from membership committee for meeting registration both online and on

site. Fourth, to Dr. Lirong Cheng, Dr. Marilyn Bui and many others for tirelessly trying to get sponsorship for CAPA activities. Fifth, to Dr. Helen Chen, Dr. Ximing Yang, Dr. Xiaoqi Lin, Dr. Lizhen Gui and Dr. Shuyuan Xiao for organizing great Friday and Saturday party. Sixth, to Dr. Fan Chen and Dr. Xiaoping Sun for capturing many great moments on films during this meeting. And last but not least, to Dr. Eric Chen and Dr. Huihong Xu for making sure all expenses for this meeting were covered and paid for.



I also want to thank our Chicago CAPA Team (Drs. Ximing Yang, Xiaoqi Lin, Helen Chen, Shuyuan Xiao, Yanxia Li, Xiaomin Sun, Jie Song, Haiyan Chen, Xianzhong Ding, etc) for being such great hosts: greeting the out of town participants for dinner, hosting wine/chat/Chicago skylight after dinner, organizing delicious chinese box lunches and great banquet, booking transportation, and serving as tour guides for Chicago's famous fireworks and NW campus.

A special thanks to Dr. Guangyu Yang's welcome speech.

Ping Tang, M.D., Ph.D.
CAPA President 2017-2018

A Letter to CAP Today

September 11, 2017

Dear Editors:

"CAP Today" provides valuable information that is important to guide the practice for many pathologists. However, an article published in the August 2017 issue, entitled "Laboratory director duties clarified in 2017 checklist" by Anne Ford has raised serious concerns among many pathologists, particularly members of the Chinese American Pathologists Association (CAPA). Specifically, we disagree with the following statement by Ms. Denise Driscoll, Director of Accreditation and Regulatory Affairs at CAP:

Sometimes it's hard to tell", the U.S. equivalent of the degree of someone trained overseas, Driscoll says, "particularly with MDs. An MD in China, for example, does not have the same educational requirements as someone does to be a physician in the U.S. Therefore, CMS requires that a formal equivalency be documented, and they give a couple of organizations that are acceptable" namely, the National Association of Credential Evaluation Services and the Association of International Credential Evaluators. "We mentioned this in the checklist before", she adds, "but people were still missing that this wasn't a general suggestion, but an actual requirement. This is a CMS requirement, and they're very strict on this, and so we're trying to make it more clear what to expect"

We believe that Ms. Driscoll's statement is incorrect, confusing and in contradiction to CMS regulations (<https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-16-18.pdf>, last accessed on Sept 7, 2017), which clearly states under the heading of Foreign Trained Personnel that "Foreign trained physicians (M.D., D.O., DDS) who are licensed to practice in the state in which the laboratory is located do not need to produce educational equivalencies. A valid State license is sufficient proof of academic achievement. "

The current CAP director assessment checklist, released in August 2017, lacks clarity in this respect. It states on page 11, 4th paragraph that *"For laboratories subject to U.S. regulations, credentials for all personnel trained outside of the U.S. must be reviewed to ensure that their training and qualifications are equivalent to CLIA requirements, with records of the review available onsite. The*

equivalency evaluations should be performed by a nationally recognized organization."

We believe this Checklist needs to be clarified in relation to the CMS regulations stipulated above. This clarification is critical for all foreign medical graduates holding a medical license and practicing in the U.S. A valid medical license signifies its holder's successful completion of medical education verification, the successful passing of all licensing exams, and the successful completion of post-graduate training with board certifications; these requirements are identical for both U.S. and international medical graduates.

Our second concern about Ms. Driscoll's statement is that her choice of China as an example of differences in medical education is inappropriate. Such a statement does make many M.D. from China who have worked hard to fulfill all the requirements and are licensed and certified to practice medicine in the U.S. feel discriminated against, although it may not have been intentional.

We are practicing medicine at a challenging time. Our profession needs to be united rather than divided. CAP, as a leading organization of pathologists, has done an outstanding job advocating for excellence in the practice of pathology and laboratory medicine worldwide. As the largest professional organization of the Chinese American pathologists and the pathologists who cherish Chinese culture with over 700 registered members across the North America, CAPA shares a common goal with CAP: the advancement of our profession to benefit patients, medicine, and science. Let us work together to resolve and clarify the issues we have raised here, to move forward to foster a united and stronger pathology community, and to ensure excellence in the practice of pathology and laboratory medicine.

Sincerely

Ping Tang, M.D., Ph.D.

CAPA President 2017-2018

Marilyn Bui, M.D., Ph.D., Guoping Cai, M.D., Zongming Eric Chen, M.D., Ph.D., Lirong Cheng, M.D., Yun Gong, M.D., Yong Andy Ke M.D., Ph.D., Huamin Wang, M.D., Ph.D., Huan-You Wang, M.D., Ph.D., Wei Xin M.D., Ph.D., Huihong Xu, M.D., Linsheng Zhang, M.D., Ph.D.

CAPA Executive Committee

Response from Denise Driscoll and A Letter from Dr. Robert C. Friedberg

I appreciate the concerns shared by the president and executive committee of CAPA. My comments as published in CAP Today and quoted in the letter are not incorrect but further clarification can be provided. The CMS does require documentation of foreign equivalency for training completed outside the United States. CMS-approved agencies must be used by the laboratory for that equivalency evaluation. Another route to documenting equivalency is to use a state medical license or state laboratory personnel license (e.g. medical technologist) when such is required by the state. This allowance is made because the state agencies perform the same equivalency evaluation that the federal law requires. Therefore, in such circumstances, the state license for physicians or medical technologists can be used as the documentation that an equivalency evaluation has been performed. Thus the statement in the CMS document, "A valid State license is sufficient proof of academic achievement." In a similar vein, the CMS accepts Department of Health and Human Services-approved boards for doctoral scientists (e.g. ABCC, ABHI, ABMM) as their applicants are also assessed for equivalency prior to acceptance.

I do sincerely apologize for calling out one country in the example in the article. My comment was made merely for illustrative purposes in bringing attention to the federal requirement as it applies to all countries outside of the United States.

The CAP Accreditation Program has updated its frequently asked questions on the CAP website to explain more clearly the documentation options that laboratories have to demonstrate compliance with the requirements—including documentation with a state medical license. The next edition of the CAP Accreditation Program checklist will contain additional clarification.

*Denise Driscoll, MS, MT(ASCP)SBB
Senior Director, Accreditation and Regulatory
Affairs
CAP Accreditation Programs
College of American Pathologists
Northfield, Ill.*

Letter on 10/6/2017

Dear Dr. Tang -

As I mentioned during our recent meeting in your office, I have strongly supported CAPA and your efforts to improve the contributions of pathologists of Chinese origin in the expanding field of Pathology. I have been honored to be invited to many of the CAPA gatherings, including every annual dinner at USCAP year since Vancouver in 2012, and I look forward to continuing my participation well after my CAP President term ends.

So when I received a note from a friend, Dr. Jiaoti Huang at Duke, about the concerns among CAPA members related to a comment in the CAP Today, I immediately contacted the CAP Senior Director of Accreditation and Regulatory Affairs, Denise Driscoll, , to make sure we had the correct information. As you can see in the attached letter from her, the choice of words was unfortunate and she certainly did not intend to single out China. CMS does require documentation of training equivalency for ALL trainees coming from outside the US provided by CMS-approved agencies such as state licensing boards.

I hope that this will alleviate some of the concerns of CAPA members that nothing specific was intended about China or the quality of pathologists and other physicians trained in China.

Sincerely,

Richard C. Friedberg, MD, PhD, FCAP
President
College of American Pathologists
325 Waukegan Road, Northfield, IL 60093
president@cap.org

CAPA Chicago Course 2017



CAPA Chicago Course 2017 (Cont'd)



CAPA Chicago Course Speakers 2017



Marilyn Bui, MD, PhD
(Moffitt Cancer Center)



Zongming Chen, MD, PhD
(Geisinger Health)




Jingmei Lin, MD, PhD
(Indiana University)



Xiaohua Qian, MD, PhD
(Harvard University)




Guoping Cai, MD
(Yale University)



Liang Cheng, MD
(Indiana University)



Xiaoqi Lin, MD, PhD
(Northwestern University)



Qinghu Ren, MD, PhD
(NYU)




Bei Yun Chen, MD, PhD
(Mayo, MN)



Yun Gong, MD
(MDACC)



Xiuli Liu, MD, PhD
(University of Florida)



Ping Tang, MD, PhD
(Loyola University)



Yingbei Chen, MD, PhD
(MSKCC)



Feng Li, MD, PhD, JD
(Med Examiner's Office)



Yan Peng, MD, PhD
(UT Southwest)



Hanlin Wang, MD, PhD
(UCLA)


CAPA Chicago Course Speakers 2017 (Cont'd)



Huamin Wang, MD, PhD
(MDACC)




Haodong Xu, MD, PhD
(University of Washington)



Ximing Yang, MD, PhD
(Northwestern University)



Hong Zhang, MD, PhD
(MKSCC)



Yun Wu, MD, PhD
(MDACC)



Huihong Xu, MD
(Boston University)




Huihui Ye, MD
(Harvard University)



Miao Zhang, MD, PhD
(MDACC)



Shuyuan Xiao, MD
(University of Chicago)



Guangyu Yang, MD, PhD
(Northwestern University)



Jay Ye, MD, PhD
(Dalh-Chase Pathol Assoc)



Yaxia Zhang, MD, PhD
(CCF)



Wei Xin, MD, PhD
(Case Western Reserve Univ)



Hua Yang, MD
(University of Calgary)



Limin Yu, MD
(Oakland University)



Ming Zhou, MD, PhD
(UT Southwest)

CAPA Chicago Course Case Presenters 2017



Haiyan Chen, MD
(Loyola University)



Xiuzhen Duan, MD
(Loyola University)



Lijuan Wang, MD
(Brown University)



Wendy Liu, MD, PhD
(Case Western Reserve Univ)



Chunhua Cui, MD
(Roxborough Memorial
Hospital)



Shunyou Gong, MD,
(Northwestern University)



Xueli Hao, MD, PhD
(St Louis Pathology
Association)



Bihong Zhao, MD, PhD
(UT Houston)

*All photos were provided by Drs. Xiaoping Sun, Fan Chen and others.

Brief Report of CAPA Dali meeting

On behalf of the CAPA, I am pleased to report to you that Dali meeting held in Oct 2017 was a great success. This meeting took one year to plan and was the first such kind meeting hosted by CAPA in China. This 1.5-day meeting had 8.5 CAP-sponsored CME credits and also similar CME from Chinese Counterpart. There are around 300 attendees including 44 CAPA members. There were total of 15 speakers/moderator and 5 case presenters including Speakers: Guoping Cai, MD; Beiyun Chen, MD, PhD; Longwen Chen, MD, PhD; Xiaohua Qian, MD, PhD; Kun Ru, MD, PhD; Dongfeng Tan, MD, PhD; Gary Tse, MD; Ping Tang, MD, PhD; Shuyuan Xiao, MD; Wei Xin, MD, PhD; Ximing Yang, MD, PhD; Linsheng Zhang, MD, PhD; Lizhi Zhang, MD, PhD; Wenxin Zheng, MD; Moderator: Yong Ke, MD, PhD; Case presenters: Haiyan Chen, MD, PhD; Dan Huang, MD, PhD; Annie Lau, MD; Mujun Yu, MD, PhD and another 8 cases from China also presented at this meeting. We want to thank all who have helped making this meeting such a success, and our co-hosts -- Yunnan Pathology Society and Dali University, and our sponsored by Huaxia, Long Island Reagents; Maixin Reagents, and supported found through Dr. Kun Ru.

Wei Xin, MD, PhD

On behalf of Education Committee of CAPA

Open Letter for Potential CAPA Sponsors

July 12, 2017

Dear Sir/Madam:

Chinese American Pathologists Association (CAPA 全美华人病理协会) is a non-for-profit organization of the Chinese American pathologists in the United States and Canada who are either in practicing or in training. Since its establishment in 2003, with the continuous and collective efforts from our past presidents, officers of all subcommittees, and all active members, CAPA has developed as a national and internationally recognized pathologist organization with over 700 members today.



CAPA consists of a very broad membership in both academic and private practice; and in Anatomic Pathology as well as Clinical Pathology; with both "experienced" and "young" pathologists. As a group, we are extremely accomplished, with many nationally and internationally known pathologists and tenured professors in all major academic institutions. Also, we have members serve as Department Chairs and Directors for anatomic pathology, cytopathology, and resident/fellowship training programs in top US/Canadian universities across the country. Some of our members also serve in high level leadership position in non-academic health organizations as well as in private sectors.

The #1 mission of CAPA is to serve our members. By providing educational opportunities (Annual Diagnostic Meeting, Weekly online educational course, independent CAPA session with other national and international pathology societies), and by promoting communication, friendship and knowledge/information exchanging during our Annual Business Meeting and other social/educational events, and by promoting young pathologists with numerous awards and career consultation; we have continually drawn more new members joining our organization. It currently has over 700 registered members, representing about half of the 1400 Chinese American practicing pathologists in the US and Canada.

As a non-for-profit organization, our funds are mainly from the generosity donations from our sponsors and the membership dues. In order to better serve our members and to provide greater impact for our community, we would appreciate any level of sponsorship from your company (please see attached form for details).

We thank you in advance for your consideration to sponsor this truly unique organization. If you have any question, please do not hesitate to contact me directly.

Sincerely yours,

Ping Tang, MD, PhD
CAPA President 2017-2018

Professor of Pathology
Director of Anatomic Pathology
Department of Pathology
Loyola University Medical Center
Maywood, IL
Phone: 708-327-3367
e-mail: ping.tang@lumc.edu

CAPA Executive Committee:

President: Ping Tang, MD, PhD; **President-Elect:** Yun Gong, MD, PhD (2018-19); **Immediate president:** Huamin Wang, MD, PhD

Executive Members: : Marilyn Bui, MD, PhD; Guoping Cai, MD, PhD; Linsheng Zhang, MD, PhD; Lirong Chen, MD; Huan-You Wang, MD, PhD; Andy Ke, MD; Wei Xin, MD, PhD **Treasurer:** Zongming Eric Chen, MD, PhD

Recent Achievements from CAPA Members

INTERNAL NOTICE

Dr. Zu-Hua Gao re-appointed Chair, Department of Pathology

We are pleased to announce that Dr. Zu-Hua Gao has been re-appointed to the position of Chair of the Department of Pathology at McGill University's Faculty of Medicine, a position he has held since 2012, from which time he also served as Pathologist-in-Chief at the McGill University Health Centre (MUHC). During his first term as Chair, Dr. Gao increased the department's research capacity from three to nine research programs and revitalized the graduate program, bringing it from eight to 24 graduate students. During this time Dr. Gao also established an Experimental Pathology Unit in the department, secured funding for clinical fellowship programs and secured endowed funds to support the department's academic activity.



An MD graduate of Qingdao Medical College in China, Dr. Gao earned his master's degree and PhD at Harbin University and Peking Union Medical College, respectively. He then traveled to North America to complete post-doctoral work at Johns Hopkins Hospital and at the University of Western Ontario. Prior to joining McGill in 2012, he was full Professor in the Department of Pathology & Laboratory Medicine and Head of the Division of Anatomical Pathology and Cytopathology at the University of Calgary.

Dr. Gao has authored more than 100 manuscripts in peer-reviewed journals, books and book chapters, including 50 peer-reviewed articles in the past five years in journals including *Nature Medicine*, *Cancer Research*, *Oncotarget* and the *Journal of Immunology*. He serves as a member on several advisory committees including at St. Mary's Hospital Centre and at the Jewish General Hospital as well as on the editorial board for three journals. During the course of his career Dr. Gao has been recognized with a number of awards including being named "Overseas Distinguished Scholar" by the City of Beijing, China in 2012 as well as receiving the Simone & Morris Fast Award for Oncology from the Research Institute of the MUHC, the Montreal General Hospital Foundation and the Royal Victoria Hospital Foundation that same year.

As Chair of the Department of Pathology at McGill's Faculty of Medicine, Dr. Gao will continue to lead the department in its education and research missions while providing effective mentoring for faculty members at various stages of their careers. He will develop strategic planning and oversee the budget while making recommendations and advising the Dean on academic recruitment, academic appointments, promotion and tenure and will oversee the undergraduate and postgraduate medical programs in the department. Dr. Gao is also expected to continue to develop his own successful research program, which focuses on studying the molecular mechanisms of colorectal cancer liver metastasis, identifying biomarkers and potential therapeutic targets for pancreatic cancer, and immune-mediated liver diseases such as primary biliary cholangitis, autoimmune hepatitis, and transplant rejection.

Please join us in congratulating Dr. Gao on a successful first term and wishing him continued success as he embarks on his second.

Dr. David Eidelman
Vice-Principal (Health Affairs)
Dean of the Faculty of Medicine

Dr. Mara Ludwig
Vice-Dean, Academic Affairs

Recent Achievements from CAPA Members

Invited Talk

The current EC members **Drs. Huamin Wang and Huan-You Wang** were invited as Keynote speakers at the 1st Annual Pathology Meeting of Mid-South, Hong Kong and Macao held from Aug 25-26, 2017 in Yichang, Hubei, China (see right).




Dr. Jiehao Zhou has given a short course at ASCP-2017 (9/6-9/8). The title of the course is 5001-17: Efficient Use of Molecular Tools in Precision Diagnostics of Bone Marrow Neoplasms.

Recent Publications

Recently Published Book:

Drs. Fan Lin, Haiyan Liu, Jun Zhang. Handbook of Practical Fine Needle Aspiration and Small Tissue Biopsies. Springer, 2018. ISBN 978-3-319-57384-7



Recent Publications:

1. Bhalla A, Mann SA, Chen S, Cummings OW, **Lin J.** Histopathological evidence of neoplastic progression of von Meyenburg complex to intrahepatic cholangiocarcinoma. Hum Pathol. 2017 Sep;67:217-224.
2. Hung YP, Lovitch SB, **Qian X.** Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics. Cancer. 2017 Aug;125(8):604-614.
3. Romano K, Pazo V, **Qian X,** Vaidya A, Maguire JH. The Road Less Traveled. N Engl J Med. 2017 Sep 21;377(12):e16.
4. **Wang L,** Harms PW, Palanisamy N, Carskadon S, Cao X, Siddiqui J, Patel RM, Zelenka-Wang S, Durham AB, Fullen DR, Harms KL, Su F, Shukla S, Mehra R, Chinnaiyan AM. Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay. Clin Cancer Res. 2017 Sep 15;23(18):5622-5630.
5. **Wang HY,** Feldman AL. Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia. Blood. 2017;130:1387.

Future Meeting

FUTURE MEETINGS - Save the day: August 25-26, 2018

The 4th CAPA Scientific Annual Meeting will be held in Saturday and Sunday, August 25-26, 2018 at Sheraton LaGuardia East Hotel located on 13520 39th Ave, Flushing, NY, 11354 (Phone: [718-6707408](tel:718-6707408)).

The meeting program will be announced in a few months.

Please mark your calendar and make every effort to participate in this exciting educational and social event.


Case of Quarter (COQ) for CAPA eNewsletter From Last Issue

Submitted by Hua Yang, Kalahari, Canada


Part 1.

Clinical History: 64 year old female, nipple “red scaling”, not respond to steroids cream. Image show no mass lesion in breast parenchyma. Wedge excisional biopsy is performed.


Part 2. H&E



Part 3. Immunohistochemical Study



Part 3. Immunohistochemical Study (Cont'd)



Part 4. Diagnosis: Glandular Paget's disease.

Part 5. Clinical management: close follow up.

Part 6. Comment:

Paget's disease of the nipple is usually characterized by single neoplastic cells or small solid clusters of cells infiltrating in the nipple epidermis.

This case is very unusual in that the neoplastic cells form glandular structures in the epidermis. The neoplastic cells are strongly cytokeratin 7, HER2, GATA3; negative for ER, PR and S100. HER2 silver in situ hybridization (SISH) is also positive, consistent with Glandular Paget's disease. Limited case reports of this pattern of Paget's disease have published (see references).

Part 7. Reference:

- 1: Shousha S. Glandular Paget's disease of the nipple. Histopathology. 2007 May;50(6):812-4. Epub 2007 Mar 21.
- 2: Moon JH, Ko HS, Byun JW, Choi GS, Shin J. Glandular Paget's Disease of the Male Nipple. Ann Dermatol. 2016 Oct;28(5):671-672.

Case of Quarter (COQ) for CAPA eNewsletter

Submitted by Henry Yang







Part 1.

This is a 45 year old lady with cervixal cancer 1.5 years ago. And now underwent chemotherapy and radiation treatment.. the plague is indurated and not painful.

Part 2. Lower Back Lesion



Part 2. H&E



What is your differential diagnosis and further work-up?

Recipes of Quarter (ROQ) for CAPA eNewsletter

中式酥餅：不添加任何香精的天然少糖芋頭(or other)酥

By Shaoying Li

材料：(約做12顆)

A. 芋頭內餡：檳榔芋頭400克(切薄片先蒸軟)，細砂糖60克，無鹽奶油30克，奶粉20克，鮮奶30ml (可有可無)(For healthy, you can use only sugar and 芋頭)

*甜度：如果想甜一點的可以自己製作餡料時調整-add more sugar

B. 油皮麵皮：中筋麵粉200克，糖粉15克，無水奶油70克，冷水105克

C. 油酥麵皮：低筋麵粉160克，無水奶油80克，芋頭香料數滴(沒有就省略 or use other)

*無水奶油部分做之前記得放室溫回軟。但不要過軟這樣麵團不好成型

做法：

【先製作芋頭內餡】 材料A. 芋頭內餡

1. 將芋頭去皮後小塊，放入電鍋內，外鍋加2.5杯水蒸熟(就是用叉子差有呈現鬆軟狀就可以)
 2. 依序將其他材料倒入拌成泥狀即可。要不要有顆粒狀就自己決定囉。完成後放入冰箱冷藏備用。
- 也可以冷凍-->要用拿出來解凍就可以。如果偏乾就在蒸一下，或是加奶油或牛奶調整即可
(For healthy, 沒有做到很綿密的芋泥-->因為那樣無鹽奶油要加很多，就放棄了)

【製作油皮麵皮】 材料B. 油皮麵皮

1. 將糖粉加入無水奶油裡，用手混合均勻。
2. 加入麵粉和糖粉繼續拌勻
3. 加入冷水，慢慢搓揉約5分鐘成為均勻柔軟不黏手的麵團就可以
4. 把搓揉好的麵團蓋上保鮮膜，放室溫醒40分鐘

【製作油酥麵皮】 材料C. 油酥麵皮

1. 把無水奶油加入低筋麵粉中，用手搓揉均勻
2. 如果有芋頭香料就可以加入讓麵團上色(or use freshly steamed芋頭, or other food color you like)，麵團就會是芋頭色的，沒有的話省略就可以。麵團會是白色的，把搓揉好的麵團蓋上保鮮膜放冰箱冰鎮40分鐘(不要搓太久喔，麵粉會出筋影響口感)

【大合體啦】

1. 把剛剛做好的芋頭內餡拿出來取約40克搓揉成一個球狀。搓完12顆芋泥球後放在一個盤子上蓋上保鮮膜備用
2. 把油酥麵皮從冰箱拿出來，平均分成6等分，並且滾成圓形(每一份約40克)；接著把油皮麵皮也分成6等分，也要滾成圓形(每一份約65克)
3. 將6個油皮麵皮依序桿開。把光滑面朝下(就是剛剛桿的那面)，在中間包上一個油酥麵皮，並捏緊收口
4. 把滾好的麵團稍微壓一下桿成橢圓形薄片，記得還要在把光滑面朝下，然後由上往下卷起，收口朝下，蓋上保鮮團讓麵團休息10分鐘(如果你的油酥麵皮一開始有滴芋頭香精的話，在這步驟桿成橢圓形薄片時就會有層次的白色和紫色顏色)
5. 把休息好的麵團桿成長形後，還是要翻面一光滑面朝下，由上往下卷起後，蓋上保鮮膜再讓它們休息20分鐘
6. 再次休息完的麵團用刀子從中間給它切下去變成兩個麵團，並且把麵團切面朝上(此時應該看得出來切面的層次了)
7. 稍微用手把麵團壓扁，然後桿成直徑約10公分的麵皮(層次會越來越明顯)
8. 將麵皮翻面(也就是有層次那面朝下)，把剛剛也在旁邊納涼的芋頭內餡放在中間包起來，縮緊收口
9. 整形完成的麵團排好放在烤盤上。(外層已經可以看到層次了)。烤箱預熱攝氏170度/華氏325度，烘烤30分鐘到外皮呈現一圈一圈明顯的紋路就可以了



CAPA Acknowledges the Following Sponsors for Their Support

项目参数 + new

ITEM	MY-A20
最大装载玻片数量	20片
最大装载试剂数量	30个
玻片条码识别	二维码
玻片位温度控制	独立温度控制
抗体滴加控制方案	高精度柱泵
是否有水平指示装置	是
是否有标签打印	有
是否有试剂自动识别	有
滴加到玻片上的位置	滴加扩散技术, 分区滴加选择
玻片清洗方式	大量液体冲洗
计算机系统	WIN8/10
试剂自行配置功能	可任意指定数量和位置
历史记录是否可追溯	是
体积	810 (W) mm x 605 (D) mm x 610 (H) mm
重量	<60kg










1. IHC Stain 1: 免疫组化染色仪 MY-A20 染色结果
 2. IHC Stain 2: 免疫组化染色仪 MY-A20 染色结果
 3. IHC Stain 3: 免疫组化染色仪 MY-A20 染色结果
 4. IHC Stain 4: 免疫组化染色仪 MY-A20 染色结果
 5. IHC Stain 5: 免疫组化染色仪 MY-A20 染色结果
 6. IHC Stain 6: 免疫组化染色仪 MY-A20 染色结果
 7. IHC Stain 7: 免疫组化染色仪 MY-A20 染色结果
 8. IHC Stain 8: 免疫组化染色仪 MY-A20 染色结果

 上海长岛抗体诊断试剂有限公司
 Shanghai Long Island Antibody Diagnostics Inc.
 中国·上海市奉贤区庄行工业园区南大路268号
 网址: www.longislandab.com 邮编: 201415
 电话: 021-64910505 传真: 021-64989771



扫一扫，马上关注我们吧

本宣传资料仅供参考，不作为任何医疗建议。产品使用说明书为准。请仔细阅读产品与服务的最新变化。请留意我们公众号。 印刷日期: 2016年7月





2⁺ new

全自动
免疫组化染色仪
MY-A20


www.longislandab.com

 全国客户服务热线
400-920-0015

Rare for you but not for Foundation Medicine

RARE/UNCOMMON SUBTYPE	PERTINENT TUMOR DRIVER	FDA APPROVED TARGETED THERAPIES	FDA APPROVED THERAPIES IN ANOTHER TUMOR TYPE
Non-Serous Ovarian Cancers, eg: Ovarian Clear cell	BRCA1/2	Olaparib	Trastuzumab, Pembrolizumab
	ERBB2		Paniparib, Pemetrexate
	FOLFIRI/5-FU		Temozolomide, Everolimus
	AKT1/2		Olaparib and others
	PARP1/2		
Pancreatobiliary Cancers:	ICR1/2		Azacitidine, Decarbazine
	ERBB2		Trastuzumab, Pembrolizumab, AZD5363
	FGFR2		Pariparib
	BRAC		Dabrafenib, Trametinib, Everolimus
	PTEN		Trastuzumab, Pembrolizumab
	SHC4/2		Trastuzumab, Pembrolizumab
	ERBB2		Trastuzumab
	BRAC		Trastuzumab, Pembrolizumab
Uncommon subtypes of breast cancer	CCND1	Palbocicb	Olaparib
	BRCA1/2		Atezolizumab, Pembrolizumab
	ERBB2		Enzalutamide, Lapatinib, Pembrolizumab, Trastuzumab
	PIK3CA, ATRX, STK11, AKT1/2, PTEN		Everolimus, Temozolomide
Salivary Gland	ERBB2		Trastuzumab, Pembrolizumab
	EGFR		Cetuximab, Lapatinib
	PTEN		Temozolomide, Everolimus
	BRCA1/2		Olaparib
	BRAC		Trastuzumab, Dabrafenib

Comprehensive genomic profiling using FoundationOne has been performed on > 16,000 uncommon tumor cases. Learn more at: **USCAP Annual Meeting Booth #541**



A Personal
Contribution from
A Senior CAPA
Member

CAPA Acknowledges the Following Sponsors for Their Support (Cont'd)



华夏病理
HUAXIA PATHOLOGY Information Net

一个有情怀的 华人病理医学社区平台

(www.ipathology.cn)

传播 交流 探索

讨论 专著 文档 品牌 教学 在线课堂 网络学院 学习资源 分享 专业资料 辅助工具 资讯 行业动态 继续教育 百科 会议
商家 产品 企业 品牌 人才 就业招聘 资讯中心 书店 书籍专著 期刊杂志 社区 网络社区 网络人脉 文献 博客

液基细胞学精准检测先行者

自助会诊业务上线啦!

2017第二届全球精准医疗(中国)峰会召开在即

“2017第二届全球精准医疗(中国)峰会(WAPACS2017)”将于2017年12月1日-2日在上海龙之梦万丽酒店盛大召开。

- HPV感染防治专家共识
- 新增病理诊断规范(病理规范)
- 最新病理诊断中上段内镜及早期癌的诊断步骤
- 胃癌病理分型
- 乳癌乳腺部位病理诊断规范



MXB®
迈新试剂

迈新提供全方位的免疫组化解决方案
免费咨询电话: 400-889-9853 / 800-858-1156